Cardiology

Worldwide Wireless ECG Devices Industry to 2025 - Declining Cost of Wireless Technologies is Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, February 1, 2021
Medical devices, Health, Mobile, Wireless, Technology, Cardiology, Medicine, Clinical medicine, Branches of biology, Cardiac electrophysiology, Electrodiagnosis, Medical monitoring, Heart diseases, Electrocardiography, Electrophysiology, Cardiac monitoring, Monitoring, Cardiovascular disease

Of these deaths, an estimated 7.4 million were due to coronary heart disease and 6.7 million were due to stroke.

Key Points: 
  • Of these deaths, an estimated 7.4 million were due to coronary heart disease and 6.7 million were due to stroke.
  • Increasing awareness regarding early detection and management of cardiovascular diseases is augmenting the demand for continuous cardiovascular ECG monitoring devices.
  • The development of commercially advanced devices, with enabled Bluetooth sensor technology and mobile app technology, is anticipated to drive the popularity of continuous cardiovascular ECG monitoring systems.
  • The United States holds the largest market share in the North American wireless ECG devices market, and it is expected to register a high growth rate over the forecast period.

Cagent Vascular Announces PRELUDE-BTK Study Results Presented at LINC Symposium: Confirms Serranator Device Novel Mechanism of Action

Retrieved on: 
Monday, February 1, 2021
Cardiology, Biotechnology, FDA, Health, Other Science, Medical devices, Research, Hospitals, Surgery, Science, Clinical trials, Interventional radiology, Angioplasty, the PRELUDE-BTK Study, Cagent Vascular

Cagent Vascular, a developer of serration technology for vessel dilatation in endovascular interventions, announced the results of its PRELUDE-BTK Study at this years LINC Symposium on January 29th.

Key Points: 
  • Cagent Vascular, a developer of serration technology for vessel dilatation in endovascular interventions, announced the results of its PRELUDE-BTK Study at this years LINC Symposium on January 29th.
  • The PRELUDE-BTK Study, was a prospective, single-arm, multi-center feasibility study to show the safety and efficacy of Serration Angioplasty.
  • Forty-six subjects were treated with the Serranator device and 53 lesions were analyzed by the core lab.
  • Carol A. Burns, President and CEO of Cagent Vascular added, These study data confirm that the Serranator device has a unique mechanism of action that led to these positive results.

Global Cardiac Pacemakers Market (2020 to 2025) - Growth, Trends, and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Monday, February 1, 2021
Health, Medical devices, Cardiology, Cardiac electrophysiology, Medical technology, Branches of biology, Embedded systems, Medical devices, Neuroprosthetics, Science and technology, Cybernetics, Artificial cardiac pacemaker, Heart

The implantable cardiac pacemakers captured the largest market share, and it is expected to grow with a lucrative growth rate, over the forecast period.

Key Points: 
  • The implantable cardiac pacemakers captured the largest market share, and it is expected to grow with a lucrative growth rate, over the forecast period.
  • The implantable pacemakers are of three major types, namely single chamber, dual chamber, and biventricular pacemakers.
  • Biventricular pacemakers are expected to gain momentum, owing to the presence of multiple leads.
  • Therefore, implantable cardiac pacemakers are expected to show a significant growth, during the forecast period.

NTT Research Names Jon Peterson MEI Lab Senior Scientist

Retrieved on: 
Monday, February 1, 2021
Cardiology, Data management, Biotechnology, Technology, Health, Medical devices, Research, Software, Nanotechnology, Science, Hardware, Academic disciplines, Artificial intelligence, Cognitive science, Computer science education, Informatics, Information science, Health informatics, Articles, Science and technology, Nippon Telegraph and Telephone

NTT Research, Inc. , a division of NTT (TYO:9432), today announced that it has named Dr. Jon Nels Peterson a Senior Scientist in its Medical & Health Informatics (MEI) Lab .

Key Points: 
  • NTT Research, Inc. , a division of NTT (TYO:9432), today announced that it has named Dr. Jon Nels Peterson a Senior Scientist in its Medical & Health Informatics (MEI) Lab .
  • View the full release here: https://www.businesswire.com/news/home/20210201005202/en/
    Dr. Jon Nels Peterson, Senior Scientist in NTT Researchs Medical & Health Informatics (MEI) Lab.
  • (Photo: Business Wire)
    We are very pleased to welcome Dr. Peterson as a Senior Scientist on our research team, said MEI Lab Director, Dr. Hitonobu Tomoike.
  • Currently, three labs are housed at NTT Research facilities in Sunnyvale: the Physics and Informatics (PHI) Lab, the Cryptography and Information Security (CIS) Lab, and the Medical and Health Informatics (MEI) Lab.

Surmodics to Webcast First Quarter Fiscal 2021 Earnings Conference Call on February 9

Retrieved on: 
Monday, February 1, 2021
General Health, Health, Cardiology, Medical devices, Web hosting, Finance, Telecommunications, World Wide Web, Corporate finance, Stock market, Lluís Companys, Conference call, Web.com, Investor relations

The Company will issue an earnings news release before the market opens that morning.

Key Points: 
  • The Company will issue an earnings news release before the market opens that morning.
  • Gary Maharaj, president and chief executive officer, and Tim Arens, senior vice president of finance and chief financial officer, will recap the first quarter fiscal 2021 financial results and accomplishments.
  • To access the webcast, go to the investor relations portion of the Companys website at https://surmodics.gcs-web.com the day of the conference call and click on the webcast icon.
  • In addition, the conference call audio and transcript will be archived on the Companys website following the call.

Indication Bioscience Granted First Patent for Statin Plus Cannabidiol (CBD) Combination

Retrieved on: 
Monday, February 1, 2021
Alternative medicine, Health, General Health, Research, Science, Pharmaceutical, Cardiology, GABAA receptor positive allosteric modulators, Drugs, Statins, Branches of biology, Chemical compounds, Hepatotoxins, Hypercholesterolemia, Niacin, Cholesterol, Discovery and development of statins, Lipid-lowering agent

According to the CDC, approximately 28% of Americans over forty years of age are prescribed a statin for hypercholesterolemia.

Key Points: 
  • According to the CDC, approximately 28% of Americans over forty years of age are prescribed a statin for hypercholesterolemia.
  • In US clinical practices, roughly 45% of patients discontinue statin use after 6 months use due to adverse effects.
  • Findings suggest that cannabinoids such as Cannabidiol in combination with statins decrease the adverse effects of statin drugs while increasing efficacy in treating cardiovascular disease such as hypercholesterolemia.
  • We are extremely pleased to have been granted the first patent for our portfolio of cannabinoid-statin combination therapies.

Cardiovascular Systems, Inc. Announces Partnership With Chansu Vascular Techologies, LLC to Develop New Drug-Coated Balloon Technology

Retrieved on: 
Monday, February 1, 2021
Health, Surgery, Cardiology, Medical devices, Everolimus, Immunosuppressants, Macrolides, Polyenes, Medicine, Chansu Vascular Technologies, LLC, Cardiovascular Systems, Inc.

Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII) announced today that it has partnered with Chansu Vascular Technologies, LLC (CVT) to develop novel peripheral and coronary everolimus drug-coated balloons (DCBs).

Key Points: 
  • Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII) announced today that it has partnered with Chansu Vascular Technologies, LLC (CVT) to develop novel peripheral and coronary everolimus drug-coated balloons (DCBs).
  • Ryan Egeland, MD, PhD, CSIs Chief Medical Officer, said, This partnership is consistent with our strategic vision to develop an innovative portfolio of new products.
  • Dr. Marco is a 25-year medical technology veteran who has spent his entire career focused on cardiovascular device development.
  • CSI is a registered trademark of Cardiovascular Systems, Inc. All other trademarks cited herein are owned by their respective owners.

FEops Announces 2.000 Patients Modelled With FEops HEARTguide™

Retrieved on: 
Monday, February 1, 2021
Cardiology, Software, Biotechnology, Surgery, Health, Medical devices, Technology, Other Health, Health informatics, Digital health, Telehealth

FEops , a digital health leader in personalized predictive planning for structural heart interventions, is proud to announce having modeled 2000 patients with FEops HEARTguide for the pre-operative planning of structural heart interventions.

Key Points: 
  • FEops , a digital health leader in personalized predictive planning for structural heart interventions, is proud to announce having modeled 2000 patients with FEops HEARTguide for the pre-operative planning of structural heart interventions.
  • Only 2 years after the launch of FEops HEARTguide, we are thrilled to see the accelerated clinical adoption of FEops HEARTguide with over 2.000 patients cases modeled.
  • This helps me to position the device at that exact location which we have determined pre-operatively with FEops HEARTguide to be the optimal one.
  • In December 2019, FEops has been awarded a grant of Euro 3.2million from the European Innovation Council (EIC) accelerator programme.

Bayer Receives Approval in the UK for Xarelto®▼ (rivaroxaban) to Treat Children With Venous Thromboembolism (VTE) and to Prevent VTE Recurrence

Retrieved on: 
Monday, February 1, 2021
Pharmaceutical, Health, Clinical trials, Cardiology, Chemical compounds, Companies, Chloroarenes, Janssen Pharmaceutica, Morpholines, Rivaroxaban, Thiophenes, Aspirin, Bayer, Economy of Germany

Dr Philip Connor, Paediatric Haematologist at Noah's Ark Children's Hospital for Wales, said: this is great news for children and their parents in the UK.

Key Points: 
  • Dr Philip Connor, Paediatric Haematologist at Noah's Ark Children's Hospital for Wales, said: this is great news for children and their parents in the UK.
  • We are delighted that rivaroxaban is now approved for use in children with VTE and for the prevention of recurrent VTE in children in the UK.
  • This provides physicians with an alternative treatment option and the ability to manage this potentially life-threatening condition in a vulnerable patient population group, said Brendon Gray, Medical Director at Bayer UK.
  • Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world.

Global Defibrillator Market (2020 to 2025) - Growth, Trends, and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Friday, January 29, 2021
Health, Medical devices, Cardiology, Cardiac electrophysiology, Branches of biology, Medical technology, Medical devices, Medicine, Neuroprosthetics, Biomedical engineering, Prosthetics, Implantable cardioverter-defibrillator, Artificial cardiac pacemaker, Cardiac resynchronization therapy, Cardiomyopathy

The implantable cardioverter defibrillator (ICD) segment accounted for the largest share in the global market.

Key Points: 
  • The implantable cardioverter defibrillator (ICD) segment accounted for the largest share in the global market.
  • The ICDs are of three major types, namely transvenous ICDs, subcutaneous ICDs, and CRT with pacemaker and ICD function.
  • Moreover, according to the Australian Institute of Health and Welfare, in 2017, approximately 4,578 people died, due to heart failure and cardiomyopathy.
  • The increasing prevalence of cardiovascular diseases in the region is expected to drive the market growth, over the forecast period.